title: Iron oxide nanoparticles for sustained delivery of anticancer agents.
abstract: We have developed a novel water-dispersible oleic acid (OA)-Pluronic-coated iron oxide magnetic nanoparticle formulation that can be loaded easily with high doses of water-insoluble anticancer agents. Drug partitions into the OA shell surrounding iron oxide nanoparticles, and the Pluronic that anchors at the OA-water interface confers aqueous dispersity to the formulation. Neither the formulation components nor the drug loading affected the magnetic properties of the core iron oxide nanoparticles. Sustained release of the incorporated drug is observed over 2 weeks under in vitro conditions. The nanoparticles further demonstrated sustained intracellular drug retention relative to drug in solution and a dose-dependent antiproliferative effect in breast and prostate cancer cell lines. This nanoparticle formulation can be used as a universal drug carrier system for systemic administration of water-insoluble drugs while simultaneously allowing magnetic targeting and/or imaging.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.
authors.forename: Tapan K
authors.initials: TK
authors.lastname: Jain
authors.forename: Marco A
authors.initials: MA
authors.lastname: Morales
authors.forename: Sanjeeb K
authors.initials: SK
authors.lastname: Sahoo
authors.forename: Diandra L
authors.initials: DL
authors.lastname: Leslie-Pelecky
authors.forename: Vinod
authors.initials: V
authors.lastname: Labhasetwar
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D006801:Humans; D008280:Magnetics; D008297:Male; D046529:Microscopy, Electron, Transmission; D008863:Microspheres; D036103:Nanotechnology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D017550:Spectroscopy, Fourier Transform Infrared; D014407:Tumor Cells, Cultured
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D005290:Ferric Compounds; C000499:ferric oxide; D004317:Doxorubicin